All In Biotech

Drug Trial Radar · NCT07694765

A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors. For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.

Conditions

  • Malignant Tumors

Interventions

  • LM-364 for injectionDrug

    Q3W, Intravenous Drip

  • TislelizumabDrug

    Q3W, Intravenous Drip

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLT)Time frame: 78 weeks
  2. Incidence of Treatment-Emergent Adverse Events (AEs)Time frame: 78 weeks
  3. Incidence of serious adverse events (SAEs)Time frame: 78 weeks
  4. Temperature (Celsius)Time frame: 78 weeks
  5. Pulse in BPM(Beat per Minute)Time frame: 78 weeks
  6. Blood Pressure in mmHgTime frame: 78 weeks
  7. Weight in KgTime frame: 78 weeks
  8. Height in centimetersTime frame: 78 weeks
  9. Blood Routine examination -> Complete Blood CountTime frame: 78 weeks
  10. Urine Routine examination ->UrinalysisTime frame: 78 weeks
  11. Blood Biochemistry test -> Electrolytes and Metabolic ParametersTime frame: 78 weeks
  12. Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT),Time frame: 78 weeks
  13. Pregnancy testTime frame: 78 weeks
  14. Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)Time frame: 78 weeks
  15. Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
  16. 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
  17. 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
  18. 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
  19. 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
  20. 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
  21. ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 78 weeks
  22. Objective Response Rate (ORR)Time frame: 130 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Macquarie University

    North Ryde, New South Wales, Australia

  • Cancer Care Wollongong Hospital

    Wollongong, New South Wales, Australia

  • Icon Cancer Centre South Brisbane

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.